Impact of first-line protease inhibitors on predicted resistance to tipranavir in HIV-1-infected patients with virological failure

BACKGROUND: Tipranavir (TPV) is a recently approved nonpeptidic protease inhibitor (PI) of HIV-1 and has been indicated for those infected with PIs-resistant HIV-1. However, in clinical practice, whether the HIV-1 from the patients with virological failure to the regimens containing first-line PIs r...

Descripción completa

Detalles Bibliográficos
Autores principales: Hsieh, Szu-Min, Chang, Sui-Yuan, Hung, Chien-Ching, Sheng, Wang-Huei, Chen, Mao-Yuan, Chang, Shan-Chwen
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2009
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2749855/
https://www.ncbi.nlm.nih.gov/pubmed/19751502
http://dx.doi.org/10.1186/1471-2334-9-154

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2749855/
https://www.ncbi.nlm.nih.gov/pubmed/19751502
http://dx.doi.org/10.1186/1471-2334-9-154

Ejemplares similares